S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
Laser breakthrough could send stock soaring 2,467% (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
Laser breakthrough could send stock soaring 2,467% (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
Laser breakthrough could send stock soaring 2,467% (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
Laser breakthrough could send stock soaring 2,467% (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Forecast, Price & News

$4.23
-0.25 (-5.58%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.13
$4.62
50-Day Range
$3.94
$7.85
52-Week Range
$2.75
$13.00
Volume
263,076 shs
Average Volume
244,886 shs
Market Capitalization
$170.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Carisma Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.4% Upside
$10.00 Price Target
Short Interest
Bearish
13.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Carisma Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.59) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

470th out of 970 stocks

Pharmaceutical Preparations Industry

211th out of 448 stocks


CARM stock logo

About Carisma Therapeutics (NASDAQ:CARM) Stock

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

CARM Price History

CARM Stock News Headlines

What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Analyst Ratings for CARISMA Therapeutics
See More Headlines
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARM
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+136.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-19,880,000.00
Pretax Margin
-612.60%

Debt

Sales & Book Value

Annual Sales
$40 million
Cash Flow
$3.71 per share
Book Value
$15.60 per share

Miscellaneous

Free Float
33,437,000
Market Cap
$170.38 million
Optionable
Not Optionable
Beta
0.86
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Steven Kelly (Age 58)
    Pres, CEO & Director
    Comp: $666k
  • Mr. Michael Klichinsky Ph.D. (Age 33)
    Pharm.D., PharmD, Co-Founder & Chief Scientific Officer
    Comp: $469k
  • Mr. Richard S. Morris CPA (Age 49)
    CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.
    Comp: $570k
  • Mr. Saar Gill M.D.
    Ph.D., Co-Founder
  • Mr. Eric H. Siegel J.D. (Age 58)
    MBA, Gen. Counsel & Corp. Sec.
  • Ms. Terry Shields
    Sr. VP of HR
  • Mr. Tom Wilton (Age 49)
    Chief Bus. Officer













CARM Stock - Frequently Asked Questions

Should I buy or sell Carisma Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARM shares.
View CARM analyst ratings
or view top-rated stocks.

What is Carisma Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 12-month target prices for Carisma Therapeutics' stock. Their CARM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 136.4% from the stock's current price.
View analysts price targets for CARM
or view top-rated stocks among Wall Street analysts.

How have CARM shares performed in 2023?

Carisma Therapeutics' stock was trading at $3.25 at the beginning of the year. Since then, CARM shares have increased by 30.2% and is now trading at $4.23.
View the best growth stocks for 2023 here
.

Are investors shorting Carisma Therapeutics?

Carisma Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 2,580,000 shares, a decline of 8.5% from the August 31st total of 2,820,000 shares. Based on an average trading volume of 234,300 shares, the days-to-cover ratio is presently 11.0 days. Currently, 13.9% of the company's stock are sold short.
View Carisma Therapeutics' Short Interest
.

When is Carisma Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our CARM earnings forecast
.

How were Carisma Therapeutics' earnings last quarter?

Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.17. The company earned $3.56 million during the quarter.

What is Carisma Therapeutics' stock symbol?

Carisma Therapeutics trades on the NASDAQ under the ticker symbol "CARM."

How do I buy shares of Carisma Therapeutics?

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Carisma Therapeutics' stock price today?

One share of CARM stock can currently be purchased for approximately $4.23.

How much money does Carisma Therapeutics make?

Carisma Therapeutics (NASDAQ:CARM) has a market capitalization of $170.38 million and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How can I contact Carisma Therapeutics?

Carisma Therapeutics' mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company can be reached via phone at 617-444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911.

This page (NASDAQ:CARM) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -